Daiichi Sankyo Inc Drug Patent Portfolio

Daiichi Sankyo Inc owns 3 orange book drugs protected by 25 US patents Given below is the list of Daiichi Sankyo Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10435404 Formulations of a compound modulating kinases 24 Jul, 2038
Active
US10941142 Formulations of a compound modulating kinases 24 Jul, 2038
Active
US10961240 Formulations of a compound modulating kinases 24 Jul, 2038
Active
US10189833 Solid forms of a compound modulating kinases 05 May, 2036
Active
US10730876 Synthesis of a compound that modulates kinases 05 May, 2036
Active
US9802932 Solid forms of a compound modulating kinases 05 May, 2036
Active
US9675549 Tablet containing composite with cyclodextrin 30 Sep, 2033
Active
US9358235 Kinase modulation, and indications therefor 08 Jun, 2033
Active
US7893075 Compounds modulating c-fms and/or c-kit activity and uses therefor 04 May, 2033
Active
US8357690 Methods of treatment using combination therapy 26 Feb, 2031
Active
US9555040 Methods of treating proliferative diseases 14 May, 2030
Active
US8836218 Methods of treatment using combination therapy 23 Mar, 2030
Active
US7968543 Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease 15 Aug, 2029
Active
US8865710 Methods of treating proliferative diseases 15 Aug, 2029
Active
US7820657 Imidazolothiazole compounds for the treatment of disease 26 Sep, 2028
Active
US8461169 Compounds modulating c-fms and/or c-kit activity 19 Apr, 2028
Active
US9149532 Pharmaceutical composition 28 Mar, 2028
Active
US8404700 Compounds modulating c-fms and/or c-kit activity and uses therefor 21 Nov, 2027
Active
US8722702 Compounds modulating c-fms and/or c-kit activity and uses therefor 21 Nov, 2027
Active
US9169250 Compounds modulating c-fms and/or c-kit activity and uses therefor 21 Nov, 2027
Active
US7365205 Diamine derivatives 18 Apr, 2027
Active
US8129374 Method of using imidazolothiazole compounds for the treatment of disease 16 Mar, 2027
Active
US8557810 Imidazolothiazole compounds for the treatment of disease 16 Mar, 2027
Active
US8883783 Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith 16 Mar, 2027
Active
US9585892 Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith 16 Mar, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Daiichi Sankyo Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 17 Jul, 2024 US9555040
Payment of Maintenance Fee, 12th Year, Large Entity 10 Jul, 2024 US8357690
Payment of Maintenance Fee, 4th Year, Large Entity 05 Feb, 2024 US10730876
Second letter to regulating agency to determine regulatory review period 02 Feb, 2024 US8557810
Second letter to regulating agency to determine regulatory review period 02 Feb, 2024 US8129374
Second letter to regulating agency to determine regulatory review period 02 Feb, 2024 US8836218
Second letter to regulating agency to determine regulatory review period 02 Feb, 2024 US8357690
Second letter to regulating agency to determine regulatory review period 02 Feb, 2024 US7820657
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US7820657
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US8129374
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US8357690
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US8557810
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US8836218
Initial letter Re: PTE Application to regulating agency 02 Oct, 2023 US7820657
Initial letter Re: PTE Application to regulating agency 02 Oct, 2023 US8557810


Daiichi Sankyo Inc Drug Patents' Oppositions Filed in EPO

Daiichi Sankyo Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 01, 2013, by Generics [Uk] Limited. This opposition was filed on patent number EP02743653A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08720658A May, 2018 Hexal AG Granted and Under Opposition
EP08720658A May, 2018 Generics [UK] Ltd Granted and Under Opposition
EP02743653A May, 2013 Generics [UK] Limited Opposition rejected


Daiichi Sankyo Inc's Family Patents

Daiichi Sankyo Inc drugs have patent protection in a total of 45 countries. It's US patent count contributes only to 20.7% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Daiichi Sankyo Inc Drug List

Given below is the complete list of Daiichi Sankyo Inc's drugs and the patents protecting them.


1. Savaysa

Savaysa is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9149532 Pharmaceutical composition 28 Mar, 2028
(3 years from now)
Active
US7365205 Diamine derivatives 18 Apr, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Savaysa's drug page


2. Turalio

Turalio is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10435404 Formulations of a compound modulating kinases 24 Jul, 2038
(13 years from now)
Active
US10941142 Formulations of a compound modulating kinases 24 Jul, 2038
(13 years from now)
Active
US10961240 Formulations of a compound modulating kinases 24 Jul, 2038
(13 years from now)
Active
US10189833 Solid forms of a compound modulating kinases 05 May, 2036
(11 years from now)
Active
US10730876 Synthesis of a compound that modulates kinases 05 May, 2036
(11 years from now)
Active
US9802932 Solid forms of a compound modulating kinases 05 May, 2036
(11 years from now)
Active
US9358235 Kinase modulation, and indications therefor 08 Jun, 2033
(8 years from now)
Active
US7893075 Compounds modulating c-fms and/or c-kit activity and uses therefor 04 May, 2033
(8 years from now)
Active
US8461169 Compounds modulating c-fms and/or c-kit activity 19 Apr, 2028
(3 years from now)
Active
US8404700 Compounds modulating c-fms and/or c-kit activity and uses therefor 21 Nov, 2027
(3 years from now)
Active
US8722702 Compounds modulating c-fms and/or c-kit activity and uses therefor 21 Nov, 2027
(3 years from now)
Active
US9169250 Compounds modulating c-fms and/or c-kit activity and uses therefor 21 Nov, 2027
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Turalio's drug page


3. Vanflyta

Vanflyta is protected by 11 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9675549 Tablet containing composite with cyclodextrin 30 Sep, 2033
(8 years from now)
Active
US8357690 Methods of treatment using combination therapy 26 Feb, 2031
(6 years from now)
Active
US9555040 Methods of treating proliferative diseases 14 May, 2030
(5 years from now)
Active
US8836218 Methods of treatment using combination therapy 23 Mar, 2030
(5 years from now)
Active
US7968543 Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease 15 Aug, 2029
(4 years from now)
Active
US8865710 Methods of treating proliferative diseases 15 Aug, 2029
(4 years from now)
Active
US7820657 Imidazolothiazole compounds for the treatment of disease 26 Sep, 2028
(3 years from now)
Active
US8129374 Method of using imidazolothiazole compounds for the treatment of disease 16 Mar, 2027
(2 years from now)
Active
US8557810 Imidazolothiazole compounds for the treatment of disease 16 Mar, 2027
(2 years from now)
Active
US8883783 Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith 16 Mar, 2027
(2 years from now)
Active
US9585892 Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith 16 Mar, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vanflyta's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List